{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:48:33Z","timestamp":1774979313122,"version":"3.50.1"},"reference-count":81,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>The incidence of ulcerative colitis, an entity belonging to the inflammatory bowel diseases, is rising worldwide. Due to the unpredictable nature of its clinical flares and the need for chronic treatment, ulcerative colitis has a huge burden of psychological impairment and reduced quality of life. Although several treatments are available to manage patients with ulcerative colitis, their efficacy is unpredictable, and long-term remission is often difficult to achieve. Moreover, the more recent and expensive drugs are not easily available in many countries. These facts have prompted the research in this field to focus on finding additional treatments for such patients. Among the putative repurposing drugs, metformin, an oral antidiabetic agent used for over seventy years, seems to represent a good candidate. While randomized controlled trials suggest that metformin, as an adjunct to conventional treatments, may improve clinical outcomes in mild-to-moderate ulcerative colitis, population-based observational and genetic studies offer mixed signals regarding its role in long-term disease modification or primary prevention. This, together with the wide availability and the low cost of metformin, might represent a good example of repurposing, as detailed in the present review. However, human mechanistic validation remains limited, underscoring the need for further research.<\/jats:p>","DOI":"10.3390\/metabo16040238","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:34:08Z","timestamp":1774974848000},"page":"238","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Back to the Future: Repurposing Metformin, a Metabolically Active Drug, to Treat Mild-to-Moderate Ulcerative Colitis"],"prefix":"10.3390","volume":"16","author":[{"given":"Elisabetta","family":"Antonelli","sequence":"first","affiliation":[{"name":"Gastroenterology and Endoscopy Unit, Santa Maria della Misericordia Hospital, 06156 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Dell\u2019Era","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Biomedical and Clinical Sciences, \u201cLuigi Sacco\u201d Hospital, University of Milano, 20157 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Maconi","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Biomedical and Clinical Sciences, \u201cLuigi Sacco\u201d Hospital, University of Milano, 20157 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0237-1812","authenticated-orcid":false,"given":"Gabrio","family":"Bassotti","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy Unit, Santa Maria della Misericordia Hospital, 06156 Perugia, Italy"},{"name":"Gastroenterology, Hepatology, and Digestive Endoscopy Section, Department of Medicine, University of Perugia, 06156 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: A review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Juhl, A.E., Westfall, M., Hebbelstrup Jensen, B., and Mirsepasi-Lauridsen, H.C. (2025). Gut microbiota in IBD: The beneficial and adverse effects of diet and medication. Nutrients, 18.","DOI":"10.3390\/nu18010009"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Villanacci, V., Del Sordo, R., Parigi, T.L., Leoncini, G., and Bassotti, G. (2023). Inflammatory bowel diseases: Does one histological score fit all?. Diagnostics, 13.","DOI":"10.3390\/diagnostics13122112"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"jjaf210","DOI":"10.1093\/ecco-jcc\/jjaf210","article-title":"Systematic review and network meta-analysis: Evaluating the impact of advanced therapies for moderate-to-severe ulcerative colitis on health-related quality of life","volume":"19","author":"Katsoula","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Marafini, I., Salvatori, S., Fonsi, A., and Monteleone, G. (2026). Optimizing drug positioning in IBD: Clinical predictors, biomarkers, and practical approaches to personalized therapy. Biomedicines, 14.","DOI":"10.3390\/biomedicines14010191"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100106","DOI":"10.1016\/j.pharmr.2025.100106","article-title":"Metformin-mechanisms of its glycemia-reducing effect","volume":"78","author":"Drewe","year":"2026","journal-title":"Pharmacol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9343(97)00254-4","article-title":"Efficacy of metformin in type II diabetes","volume":"103","author":"Garber","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12026-025-09601-0","article-title":"Metformin suppresses gammadelta T17 cell differentiation alleviating DSS-induced colitis","volume":"73","author":"Sun","year":"2025","journal-title":"Immunol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1128\/AEM.01357-14","article-title":"Effect of metformin on metabolic improvement and gut microbiota","volume":"80","author":"Lee","year":"2014","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lee, S.Y., Lee, S.H., Yang, E.J., Kim, E.K., Kim, J.K., Shin, D.Y., and Cho, M.L. (2015). Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17\/Treg balance. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135858"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jcmm.13342","article-title":"Metformin protects against intestinal barrier dysfunction via AMPK\u03b11-dependent inhibition of JNK signalling activation","volume":"22","author":"Deng","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1042\/CS20180167","article-title":"Metformin inhibits inflammatory signals in the gut by controlling AMPK and p38 MAP kinase activation","volume":"132","author":"Dinallo","year":"2018","journal-title":"Clin. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3724\/zdxbyxb-2021-0242","article-title":"Metformin alleviates intestinal epithelial barrier damage by inhibiting endoplasmic reticulum stress-induced cell apoptosis in colitis cell model","volume":"50","author":"Wang","year":"2021","journal-title":"J. Zhejiang Univ. Med. Sci"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Youssef, M.E., Abd El-Fattah, E.E., Abdelhamid, A.M., Eissa, H., El-Ahwany, E., Amin, N.A., Hetta, H.F., Mahmoud, M.H., Batiha, G.E., and Gobba, N. (2021). Interference with the AMPK\u03b1\/mTOR\/NLRP3 signaling and the IL-23\/IL-17 axis effectively protects against the dextran sulfate sodium intoxication inrRats: A new paradigm in empagliflozin and metformin reprofiling for the management of ulcerative colitis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.719984"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chen, L., Wang, J., You, Q., He, S., Meng, Q., Gao, J., Wu, X., Shen, Y., Sun, Y., and Wu, X. (2018). Activating AMPK to restore tight junction assembly in intestinal epithelium and to attenuate experimental colitis by metformin. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00761"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Olivier, S., Diounou, H., Pochard, C., Frechin, L., Durieu, E., Foretz, M., Neunlist, M., Rolli-Derkinderen, M., and Viollet, B. (2022). Intestinal epithelial AMPK deficiency causes delayed colonic epithelial repair in DSS-induced colitis. Cells, 11.","DOI":"10.3390\/cells11040590"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/gutjnl-2012-303839","article-title":"An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice","volume":"63","author":"Shin","year":"2014","journal-title":"Gut"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, Y., Jia, X., and Cong, B. (2024). Advances in the mechanism of metformin with wide-ranging effects on regulation of the intestinal microbiota. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1396031"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Caturano, A., Nilo, D., Nilo, R., Sircana, M.C., Erul, E., Zieli\u0144ska, K., Russo, V., Santonastaso, E., and Sasso, F.C. (2026). Old drug, new science: Metformin and the future of pharmaceutics. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18010077"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ke, H., Li, F., Deng, W., Li, Z., Wang, S., Lv, P., and Chen, Y. (2021). Metformin exerts anti-inflammatory and mucus barrier protective effects by enriching Akkermansia muciniphila in mice with ulcerative colitis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.726707"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/JOE-13-0381","article-title":"Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling","volume":"220","author":"Kim","year":"2014","journal-title":"J. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.dld.2011.02.019","article-title":"Ultrasonographic assessment of colonic wall in moderate-severe ulcerative colitis: Comparison with endoscopic findings","volume":"43","author":"Antonelli","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/ecco-jcc\/jjw076","article-title":"Fibrotic and vascular remodelling of colonic wall in patients with active ulcerative colitis","volume":"10","author":"Ippolito","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1053\/j.gastro.2022.01.023","article-title":"What does disease progression look like in ulcerative colitis, and how might it be prevented?","volume":"162","author":"Torres","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Villanacci, V., Maconi, G., Laschi, L., and Bassotti, G. (2025). Diagnosing ulcerative colitis: Should we go beyond the surface?. J. Clin. Med., 14.","DOI":"10.3390\/jcm14113690"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/10520295.2020.1776896","article-title":"Metformin alleviates experimental colitis in mice by up-regulating TGF-\u03b2 signaling","volume":"96","author":"Liu","year":"2021","journal-title":"Biotech. Histochem."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wang, Z., Yang, H., Chen, S., Zheng, D., Liu, X., Jiang, Q., and Chen, Y. (2022). Metformin ameliorates chronic colitis-related intestinal fibrosis via inhibiting TGF-\u03b21\/Smad3 signaling. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.887497"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Noh, J.Y., Farhataziz, N., Kinter, M.T., Yan, X., and Sun, Y. (2024). Colonic Dysregulation of Major Metabolic Pathways in Experimental Ulcerative Colitis. Metabolites, 14.","DOI":"10.3390\/metabo14040194"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wang, H., Xie, Q., Xie, Y., and Luo, W. (2025). Comprehensive proteomic profiling of intestinal tissues in patients with ulcerative colitis. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1537168"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kang, Y.H., Tucker, S.A., Quevedo, S.F., Inal, A., Korzenik, J.R., and Haigis, M.C. (2022). Metabolic analyses reveal dysregulated NAD+ metabolism and altered mitochondrial state in ulcerative colitis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0273080"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e38403","DOI":"10.1016\/j.heliyon.2024.e38403","article-title":"Utilizing an integrated bioinformatics and machine learning approach to uncover biomarkers linking ulcerative colitis to purine metabolism-related genes","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16333","DOI":"10.1021\/acs.jafc.5c00637","article-title":"Multiomics Analysis of Bacteroides cellulosilyticus Anticolitis via Gut Microbiota Metabolite-Mediated PI3K-Akt Signaling Pathway","volume":"73","author":"Mu","year":"2025","journal-title":"J. Agric. Food Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17562848241239580","DOI":"10.1177\/17562848241239580","article-title":"Systematic review of metabolomic alterations in ulcerative colitis: Unveiling key metabolic signatures and pathways","volume":"17","author":"Liu","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/ecco-jcc\/jjaa227","article-title":"Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review","volume":"15","author":"Gallagher","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hyun, C.K. (2021). Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179139"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.chom.2023.12.013","article-title":"Linking microbial genes to plasma and stool metabolites uncovers host-microbial interactions underlying ulcerative colitis disease course","volume":"32","author":"Schirmer","year":"2024","journal-title":"Cell Host Microbe"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2424913","DOI":"10.1080\/19490976.2024.2424913","article-title":"Differential contributions of the gut microbiota and metabolome to pathomechanisms in ulcerative colitis: An in vitro analysis","volume":"16","author":"Poppe","year":"2024","journal-title":"Gut Microbes"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e44206","DOI":"10.1097\/MD.0000000000044206","article-title":"Mendelian randomization study: Metabolites as mediators of inflammatory factors in ulcerative colitis","volume":"104","author":"Cai","year":"2025","journal-title":"Medicine"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Sankarasubramanian, J., Ahmad, R., Avuthu, N., Singh, A.B., and Guda, C. (2020). Gut Microbiota and Metabolic Specificity in Ulcerative Colitis and Crohn\u2019s Disease. Front. Med., 7.","DOI":"10.3389\/fmed.2020.606298"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Liu, Y., Jiang, H., Gu, Y., Li, Y., and Ding, X. (2025). Multiple Comprehensive Analyses Identify the Protective Role and Diagnostic Signature of Mannose Metabolism in Ulcerative Colitis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199443"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Binsaleh, A.Y., El-Haggar, S.M., Hegazy, S.K., Maher, M.M., Bahgat, M.M., Elmasry, T.A., Alrubia, S., Alsegiani, A.S., Eldesoqui, M., and Bahaa, M.M. (2025). The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: A randomized controlled study. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1507009"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Molavi, M., Amin, B., and Sahebkar, M. (2025). Metformin as a potential adjunct in the treatment of mild-to-moderate ulcerative colitis: A double-blind, randomized, placebo-controlled pilot study. Intern. Emerg. Med., Epub ahead of printing.","DOI":"10.1007\/s11739-025-04222-9"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"112541","DOI":"10.1016\/j.intimp.2024.112541","article-title":"Repurposing metformin as adjuvant therapy in patients with ulcerative colitis treated with mesalamine: A randomized controlled double-blinded study","volume":"138","author":"Hegazy","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00535-022-01896-2","article-title":"Metformin use is not associated with reduced risk of older onset inflammatory bowel disease: A Danish nationwide population-based study","volume":"57","author":"Allin","year":"2022","journal-title":"J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e41400","DOI":"10.1097\/MD.0000000000041400","article-title":"Causal association of metformin treatment with diverse immune-mediated inflammatory diseases: A Mendelian randomization analysis","volume":"104","author":"Liao","year":"2025","journal-title":"Medicine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/ibd\/izae147","article-title":"Metformin is associated with improved inflammatory bowel disease outcomes in patients with type 2 diabetes mellitus: A propensity-matched cohort study","volume":"31","author":"Petrov","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ecco-jcc\/jjaa136","article-title":"Metformin use is associated with a lower risk of inflammatory bowel disease in patients with type 2 diabetes mellitus","volume":"15","author":"Tseng","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_51","first-page":"1","article-title":"Effect of Indole-3-carbinol and\/or metformin on female patients with ulcerative colitis (premalignant condition): Role of oxidative stress, apoptosis and proinflammatory cytokines","volume":"1","author":"Kabel","year":"2017","journal-title":"J. Cancer Res. Treat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"113683","DOI":"10.1016\/j.intimp.2024.113683","article-title":"Metformin alleviates colitis-associated colorectal cancer via inhibition of the TLR4\/MyD88\/NF\u03baB\/MAPK pathway and macrophage M2 polarization","volume":"144","author":"Lai","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.7150\/jca.101251","article-title":"Metformin may improve intestinal mucosal barrier function and help prevent and reverse colorectal cancer in mice","volume":"16","author":"Wang","year":"2025","journal-title":"J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejim.2016.05.027","article-title":"Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis","volume":"33","author":"Rokkas","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/CEJ.0000000000000872","article-title":"Association of metformin and statin uses with the prognosis of colon cancer: A meta-analysis","volume":"33","author":"Xu","year":"2024","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/jnci\/djaf165","article-title":"Metformin use and risk of colorectal cancer in patients with inflammatory bowel disease: A nationwide, population-based cohort study","volume":"117","author":"Huang","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5217\/ir.2023.00062","article-title":"Risk of malignancies and chemopreventive effect of statin, metformin, and aspirin in Korean patients with ulcerative colitis: A nationwide population-based study","volume":"23","author":"Oh","year":"2025","journal-title":"Intest. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: Clinical use in type 2 diabetes","volume":"60","author":"Inzucchi","year":"2017","journal-title":"Diabetologia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12325-021-01979-1","article-title":"Efficacy and safety of metformin versus the other oral antidiabetic drugs in Japanese type 2 diabetes patients: A network meta-analysis","volume":"39","author":"Nishimura","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.15663","article-title":"Metformin: Therapeutic profile in the treatment of type 2 diabetes","volume":"26","author":"Bailey","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1592\/phco.21.17.1422.34430","article-title":"Metformin as a cause of late-onset chronic diarrhea","volume":"21","author":"Foss","year":"2001","journal-title":"Pharmacotherapy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1358\/dot.2008.44.4.1138124","article-title":"Metformin: A review","volume":"44","author":"Strack","year":"2008","journal-title":"Drugs Today"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14740338.2013.752813","article-title":"A review of the efficacy and safety of oral antidiabetic drugs","volume":"12","author":"Stein","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","article-title":"Clinical pharmacokinetics of metformin","volume":"30","author":"Scheen","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc15-0488","article-title":"The primary glucose-lowering effect of metformin resides in the gut, not the circulation: Results from short-term pharmacokinetic and 12-week dose-ranging studies","volume":"39","author":"Buse","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2337\/db14-1388","article-title":"Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: A GoDARTS study","volume":"64","author":"Dujic","year":"2015","journal-title":"Diabetes"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10151-013-1106-8","article-title":"Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome","volume":"18","author":"Stasi","year":"2014","journal-title":"Tech. Coloproctology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bph.15930","article-title":"Role of 5-HT in the enteric nervous system and enteroendocrine cells","volume":"182","author":"Spencer","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Huang, Y., Lou, X., Jiang, C., Ji, X., Tao, X., Sun, J., and Bao, Z. (2022). Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1044030"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00125-008-1053-5","article-title":"Metformin and the intestine","volume":"51","author":"Bailey","year":"2008","journal-title":"Diabetologia"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Han, Y., and Yun, C.C. (2022). Metformin inhibits Na+\/H+ exchanger NHE3 resulting in intestinal water loss. Front. Physiol., 13.","DOI":"10.3389\/fphys.2022.867244"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1463-1326.2003.00252.x","article-title":"Differential effects of metformin on bile salt absorption from the jejunum and ileum","volume":"5","author":"Carter","year":"2003","journal-title":"Diabetes Obes. Metab."},{"key":"ref_74","first-page":"1073","article-title":"Prevalence of metformin-induced gastrointestinal problems","volume":"76","author":"Sadeeqa","year":"2019","journal-title":"Acta Pol. Pharm.\u2013Drug Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Niknejad, A., Hosseini, Y., Nazari Manesh, M.A., Navabakhsh, M., Peyrovinasab, A., Mavaddat, H., Miri, M.S., Hosseini, M., B\u00fcsselberg, D., and Abdolghaffari, A.H. (2025). Therapeutic impacts of oral anti-diabetic drugs on Inflammatory Bowel Disease (IBD), a comprehensive review of clinical and preclinical studies. Naunyn Schmiedebergs Arch. Pharmacol., in press.","DOI":"10.1007\/s00210-025-04591-0"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s13300-021-01058-2","article-title":"Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis","volume":"12","author":"Grant","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"42","DOI":"10.17925\/EE.2024.20.2.7","article-title":"Metformin Use and Vitamin B12 Deficiency in People with Type 2 Diabetes. What Are the Risk Factors? A Mini-systematic Review","volume":"20","author":"Atkinson","year":"2024","journal-title":"touchREV. Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jcag\/gwac035","article-title":"Preparing for Colonoscopy in People with Diabetes: A Review with Suggestions for Clinical Practice","volume":"6","author":"Chirila","year":"2022","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"109230","DOI":"10.1016\/j.intimp.2022.109230","article-title":"Repurposing metformin as a potential treatment for inflammatory bowel disease: Evidence from cell to the clinic","volume":"112","author":"Wanchaitanawong","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00535-023-01983-y","article-title":"Antidiabetic drugs for IBD: A long but promising road ahead for drug repositioning to target intestinal inflammation","volume":"58","author":"Shinzaki","year":"2023","journal-title":"J. Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Antonelli, E., and Bassotti, G. (2026). Repurposing metformin: Another possible bullet to target cheaply ulcerative colitis. Intern. Emerg. Med., in press.","DOI":"10.1007\/s11739-025-04241-6"}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/4\/238\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:53:15Z","timestamp":1774975995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/4\/238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["metabo16040238"],"URL":"https:\/\/doi.org\/10.3390\/metabo16040238","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}